ONCOLOGICA is a consortium comprising eight biopharmaceutical and biotechnological companies of principally Spanish capitalization. The ONCOLOGICA Consortium of eight Spanish companies is headed by the biopharmaceutical company PharmaMar S.A. The consortium is currently conducting the “New strategies based on Biomarkers for cancer detection and prognostic, response prediction and the development of new drugs” project. Research on biomarkers represents the common theme of the important technological efforts of this project aimed at the development of new oncologic therapies based on personalized medicine.

For the next four years the project will employ the talents of multidisciplinary teams of biologists, chemists, pharmacists, and bioinformaticians including scientists from over twenty leading academic institutions in cancer research. They will collaborate closely, with the goal of positioning themselves in the forefront of biomarker research.

The ONCOLOGICA Consortium represents an opportunity for the integration of efforts aimed to increase the international competitiveness of its member companies. Sharing the existing know-how and technologies within the Consortium, together with the specialization of the associated academic groups, will provide added value to the R+D+i activities of consortium members.